Spyre Therapeutics CFO Scott Burrows sells $2.26m in stock
Spyre Therapeutics CFO Scott Burrows sold 25,000 shares for $2.26M in early October 2026, following stock option exercises. Shares were sold at prices ranging from $89.00 to $93.59. The company's stock has surged 486% over the past year, but is considered overvalued. Recent clinical trial results were mixed, with analysts offering varied ratings and price targets, including Buy ratings from Guggenheim, Stifel, and JPMorgan.
How this was made
The 30-second read
Why it matters
The insider sale adds a bearish nuance to an otherwise upbeat clinical‑trial narrative.
Market read
Primary relevance is the insider sale; secondary relevance from trial data and analyst ratings.
What to watch
Recent positive trial results and analyst upgrades could offset the negative signal from the sale.
Background
Spyre Therapeutics (NASDAQ:SYRE) reported a CFO insider sale and recent Phase II trial updates with mixed analyst reactions.
Ticker impact
CFO Scott Burrows sold 25,000 shares for $2.26 M via a Form 4 filing, indicating insider selling pressure.
likely pressure as the market prices in the insider sale
The CFO's sizable sale under a 10b5‑1 plan may prompt traders to anticipate further dilution or weaker outlook.
Market effects
Minimal; biotech sector not broadly affected by a single insider sale.
None; impact confined to SYRE shareholders.
Low; no macro or global implications.
Counterpoint
Insider sales may be routine and unrelated to fundamentals; the stock could still rally on trial data.
Key entities
- companySpyre Therapeutics
Biotech firm developing inflammatory disease therapies.
- executiveScott Burrows
Chief Financial Officer of Spyre Therapeutics.
